RNS Number:5268S
Deltex Medical Group PLC
26 November 2003


            Deltex Medical Group plc ("Deltex Medical" / "Company")


                   LAUNCH AND FIRST SALES OF PAEDIATRIC PROBE


Chichester, UK - Deltex Medical (AIM LSE: DEMG) today announces the launch and
first sales of a new probe, the pDP72, which enables its CardioQTM cardiac
function and fluid status monitoring solution to be used in children.


Chief Executive Andy Hill commented:


"The launch in the UK of this new dedicated paediatric probe means that Deltex
Medical is able to provide a minimally invasive, safe and effective means of
monitoring cardiac performance and fluid status in this vulnerable group of
young patients.


"We are in discussions with a number of doctors interested in purchasing these
probes and have already made sales to doctors at the Royal Alexandra Hospital
for Sick Children in Brighton and to Nobles Hospital in the Isle of Man.  These
doctors will be able to ensure that paediatric patients undergoing surgery and
those in intensive care can receive the benefits of haemodynamic optimisation
previously only available to the adult population.


"The Company is continuing to develop a range of probe solutions to meet
specific clinical needs.  The paediatric probe is designed for use on patients
aged from two to sixteen years undergoing moderate and major surgery or critical
care.  The launch of this probe further demonstrates the considerable strength
of the CardioQTM system to be adaptable to solutions tailored to different
specialist applications."


Enquiries

Deltex Medical Group plc

Nigel Keen, Chairman             nigel.keen@deltexmedical.com
01243 774 837

Andy Hill, Chief Executive       andy.hill@deltexmedical.com
01243 774 837

Ewan Phillips, Finance Director            ewan.phillips@deltexmedical.com
01243 774 837


Notes for Editors


Deltex Medical primarily develops, assembles and markets a cardiac function
monitor and therapy guidance device, the CardioQTM ('CardioQTM'/'Monitor'). The
CardioQTM incorporates the Company's proprietary software and a small diameter,
easy-to-use, minimally invasive, disposable oesophageal probe that is used for
transmitting and receiving an ultra-sound ('Doppler') signal. By using this
Doppler technology, the CardioQTM provides clinicians with the ability to
haemodynamically optimise critically ill patients and those undergoing routine
moderate to major surgery through the controlled administration of fluid and
drugs. Haemodynamic optimisation has been scientifically proven to improve the
speed and quality of patient recovery and reduce hospital stay.


There are already over 1000 CardioQTMs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 75 clinical publications on the use of the CardioQ
TM which have repeatedly:-

  * validated the results of the Monitor against known standards for measuring
cardiac output, demonstrating that the technology works


  * proved that the CardioQTM works in a wide range of surgical procedures


  * demonstrated that the Company's technology provides significant health and
economic benefits by helping to reduce post-operative complications and length
of hospital stays by an average of 30 to 40 per cent for a wide range of
patients.

                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PRLNKAKDNBDDQDB